Meeting on the Med 2021 | Off-the-shelf iPSC therapies for solid tumors

Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, discusses the benefits of utilizing allogenic stem cell platforms over autologous approaches that involve the need for patients to undergo leukapheresis and a time-consuming cell manufacturing process, which is an issue in patients with late-stage cancer. Off-the-shelf allogeneic induced pluripotent stem cell (iPSC) platforms offer the potential for consistent, genetically engineered therapies that can be offered to patients more quickly. Adaptimmune’s allogeneic platform is being leveraged to develop off-the-shelf products that function in the same manner as their existing autologous products already being evaluated in clinical trials for solid tumors. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.